Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?
Journal of Veterinary Pharmacology and Therapeutics · 2025
DOI: 10.1111/jvp.13472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2025. Verfasst von Jonathan Elliott und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, UK. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Cat Diseases, Dog Diseases, Kidney Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium glucose transporter type 2 (SGLT2) inhibitors have been introduced into human medicine where their beneficial effects go beyond the expected improvement in blood glucose control. These drugs appear to prevent progression of both cardiovascular and kidney diseases, not only in diabetic but also in non‐diabetic human patients. As these drugs have received conditional approval for use in diabetic cats and are being used in other veterinary species, the intriguing question as to whether they will have similar cardioprotective and nephroprotective effects in dogs and cats is being asked. The primary mechanism(s) by which SGLT2 inhibitors are cardio‐ and nephroprotective remain to be fully characterized. This paper reviews these suggested mechanisms in the context of the pathophysiology of progressive cardiovascular and kidney diseases in dogs and cats with the goal of predicting which categories of non‐diabetic veterinary patients these drugs might be of most benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, UK.
- Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Jonathan Elliott
Zitieren
APA
Elliott, J., & Oyama, M. A. (2025). Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13472
Vancouver
Elliott J, Oyama MA. Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?. Journal of Veterinary Pharmacology and Therapeutics. 2025. doi:10.1111/jvp.13472
BibTeX
@article{Elliott2025,
author = {Elliott, Jonathan and Oyama, Mark A},
title = {Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2025},
doi = {10.1111/jvp.13472}
}
EUVIMED